-
摘要: 近年来，生物技术药研发涌现于心血管病治疗，包括多肽、单克隆抗体、反义寡核苷酸、小干扰核糖核酸、基因编辑疗法和治疗性疫苗。这些信息令人鼓舞，部分药物已经批准临床应用，部分药物仍在进行临床研究，有望成为治疗心血管病的生物技术药，提高心血管病患者治疗的有效性和依从性。Abstract: In recent years, biotechnology drugs are emerging in the treatment of cardiovascular disease, include polypeptides, monoclonal antibody(mAb), antisense oligonucleotide(ASO), small interfere ribonucleic acid(siRNA), gene editing therapy, and therapeutic vaccine(TAV). These data are very encouraging, some drugs have been approved for clinical use; however, further studies are needed to introduce those drugs into clinical practice. It is expected to be the new kind of biotechnological drugs for the treatment of cardiovascular diseases, to improve the effectiveness and compliance of treatment in patients with cardiovascular disease.
-
-
[1] Gareri C, Polimeni A, Giordano S, et al. Antisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias[J]. J Clin Med, 2022, 11(13).
[2] 彭司勋. 药物化学——回顾与发展[M]. 北京: 人民卫生出版社. 2002年.
[3] Rasmussen A, Hammou A, Poulsen TF, et al. Definition, categorization, and environmental risk assessment of biopharmaceuticals[J]. Sci Total Environ, 2021, 789: 147884. doi: 10.1016/j.scitotenv.2021.147884
[4] Plotkin S. History of vaccination[J]. Proc Natl Acad Sci U S A, 2014, 111(34): 12283-12287. doi: 10.1073/pnas.1400472111
[5] 邱志华, 胡夏君, 周彦兆, 等. 心血管病治疗性疫苗的进展与展望[J]. 中国科学: 生命科学, 2022, 52(5): 781-794. https://www.cnki.com.cn/Article/CJFDTOTAL-JCXK202205018.htm
[6] Katzmann JL, Gouni-Berthold I, Laufs U. PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects[J]. Front Physiol, 2020, 11: 595819. doi: 10.3389/fphys.2020.595819
[7] Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease[J]. N Engl J Med, 2017, 377(12): 1119-1131. doi: 10.1056/NEJMoa1707914
[8] Mansoor M, Melendez AJ. Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics[J]. Gene Regul Syst Bio, 2008, 2: 275-295.
[9] Matsuda S, Keiser K, Nair JK, et al. siRNA conjugates carrying sequentially assembled trivalent N-acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes[J]. ACS Chem Biol, 2015, 10(5): 1181-1187. doi: 10.1021/cb501028c
[10] Wittrup A, Lieberman J. Knocking down disease: a progress report on siRNA therapeutics[J]. Nat Rev Genet, 2015, 16(9): 543-552. doi: 10.1038/nrg3978
[11] Schroeder A, Levins CG, Cortez C, et al. Lipid-based nanotherapeutics for siRNA delivery[J]. J Intern Med, 2010, 267(1): 9-21. doi: 10.1111/j.1365-2796.2009.02189.x
[12] Uijl E, Mirabito Colafella KM, Sun Y, et al. Strong and Sustained Antihypertensive Effect of Small Interfering RNA Targeting Liver Angiotensinogen[J]. Hypertension, 2019, 73(6): 1249-1257. doi: 10.1161/HYPERTENSIONAHA.119.12703
[13] Schnell O, Battelino T, Bergenstal R, et al. Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes[J]. Cardiovasc Diabetol, 2022, 21(1): 50. doi: 10.1186/s12933-022-01481-0
[14] Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease[J]. N Engl J Med, 2017, 376(18): 1713-1722. doi: 10.1056/NEJMoa1615664
[15] Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome[J]. N Engl J Med, 2018, 379(22): 2097-2107. doi: 10.1056/NEJMoa1801174
[16] Ray KK, Wright RS, Kallend D, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol[J]. N Engl J Med, 2020, 382(16): 1507-1519. doi: 10.1056/NEJMoa1912387
[17] O'Donoghue ML, Rosenson RS, Gencer B, et al. Small Interfering RNA to Reduce Lipoprotein(a)in Cardiovascular Disease[J]. N Engl J Med, 2022, 387(20): 1855-1864. doi: 10.1056/NEJMoa2211023
[18] Huang S, Taubel J, Fiore G, et al. Abstract 14387: Dose-relatedreductions in blood pressure with a rna interference(rnai)therapeutic targeting angiotensinogen in hypertensive patients: Interim results from a first-in-human phase 1 study of aln-agt01[J]. Circulation, 2020, 142: A14387. doi: 10.1161/circ.142.suppl_3.14387.
[19] Ranasinghe P, Addison ML, Webb DJ. Small Interfering RNA Therapeutics in Hypertension: A Viewpoint on Vasopressor and Vasopressor-Sparing Strategies for Counteracting Blood Pressure Lowering by Angiotensinogen-Targeting Small Interfering RNA[J]. J Am Heart Assoc, 2022, 11(20): e027694. doi: 10.1161/JAHA.122.027694
[20] Graham MJ, Lee RG, Brandt TA, et al. Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides[J]. N Engl J Med, 2017, 377(3): 222-232. doi: 10.1056/NEJMoa1701329
[21] Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a)Reduction in Persons with Cardiovascular Disease[J]. N Engl J Med, 2020, 382(3): 244-255. doi: 10.1056/NEJMoa1905239
[22] Gaudet D, Brisson D, Tremblay K, et al. Targeting APOC3 in the familial chylomicronemia syndrome[J]. N Engl J Med, 2014, 371(23): 2200-2206. doi: 10.1056/NEJMoa1400284
[23] Gillmore JD, Gane E, Taubel J, et al. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis[J]. N Engl J Med, 2021, 385(6): 493-502. doi: 10.1056/NEJMoa2107454
[24] Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes[J]. N Engl J Med, 2016, 375(4): 311-322. doi: 10.1056/NEJMoa1603827
[25] Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes[J]. N Engl J Med, 2016, 375(19): 1834-1844. doi: 10.1056/NEJMoa1607141
[26] Tissot AC, Maurer P, Nussberger J, et al. Effect of immunisation against angiotensin Ⅱ with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase Ⅱa study[J]. Lancet, 2008, 371(9615): 821-827. doi: 10.1016/S0140-6736(08)60381-5
[27] Wang Y, Fan Z, Xu C, et al. Anti-ATR001 monoclonal antibody ameliorates atherosclerosis through beta-arrestin2 pathway[J]. Biochem Biophys Res Commun, 2021, 544: 1-7. doi: 10.1016/j.bbrc.2021.01.054
[28] Ma ZH, Mao CF, Chen X, et al. Peptide vaccine against ADAMTS-7 ameliorates atherosclerosis and postinjury neointima hyperplasia[J]. Circulation, 2022. doi. org/10.1161/CIRCULATIONAHA. 122.061516 doi: 10.1161/CIRCULATIONAHA.122.061516
-
下载:
图(1)
计量
- 文章访问数: 1397
- PDF下载数: 373
- 施引文献: 0